Please ensure Javascript is enabled for purposes of website accessibility

Here's Why MannKind Corporation Remained Stuck in Reverse and Lost 24% in February

By Sean Williams - Mar 7, 2017 at 12:27PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

MannKind's reverse stock split gave investors the blues.

What happened

Shares of MannKind (NASDAQ: MNKD), a biopharmaceutical company primarily focused on the treatment of diabetes, plummeted 24% in February, according to data from S&P Global Market Intelligence. Despite the company offering a number of upbeat updates, one catalyst provided much of the downside spark.

So what

If investors choose to point their fingers, the blame for another poor month lies with MannKind's decision in early February to announce that it was tinkering with the idea of a reverse stock split, which has since happened. On March 3, MannKind reverse split its common stock 1-for-5.

Worried man looking at a plunging stock chart.

Image source: Getty Images.

Why such indigestion toward the reverse split announcement? Typically, stocks only reverse split after they've been in a long downward spiral and they're at risk of being booted off a reputable stock exchange. With MannKind's stock trading well below $1 per share prior to the split, it was at risk of being booted off of the Nasdaq and onto an over-the-counter exchange, which likely would not have helped its valuation.

It's also worth noting that when companies dip below $1 per share, most institutions and hedge funds won't buy shares. Thus, the reverse split is a defensive maneuver by management to make a company's stock more attractive to institutional investors, as well as remain listed on a reputable stock exchange.

On the plus side, MannKind announced new Titration packs containing varied doses of its Food and Drug Administration-approved inhalable diabetes drug, Afrezza. It also announced that it would be abandoning its contract sales organization in favor of an in-house marketing team for Afrezza.

Now what

While it's encouraging to see MannKind embracing an internal sales team for Afrezza, as well as varied dosing options which might make Afrezza more attractive to physicians and consumers, the company's lead drug is still one of the biggest launch disappointments of all time.

Afrezza inhaler.

Image source: MannKind.

On paper, Afrezza looked as if it could be a blockbuster. It's indicated for type 1 or 2 diabetes, it's an inhalable product (meaning a reduced need for needles), it's fast-acting, and it's metabolized through the body in superior fashion to other insulins. Unfortunately, Afrezza was also pricier than traditional therapies, and it didn't have the rapport with physicians that existing therapies had. This has doomed Afrezza to a pittance in sales since its launch.

Making matters more complicated is the fact that MannKind is slowly whittling away at its available cash and capital. MannKind ended the third quarter with $35.5 million in cash, $30.1 million in credit available from the Mann Group, and $50 million in at-the-market common stock issuances. It also added $16.7 million from the sale of real estate in February and $30.6 million from Sanofi, its former licensing partner for Afrezza. This might sound like a lot of capital, but it's not, given how rapidly MannKind has burned through cash. In all likelihood, MannKind's cash raises mean even more dilution for existing shareholders.

Though MannKind has new ideas up its sleeve, the story continues to remain the same for investors: stay far, far away from MannKind's stock.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

MannKind Corporation Stock Quote
MannKind Corporation
MNKD
$3.88 (-2.51%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.